<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152306</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FAC-CT-301</org_study_id>
    <nct_id>NCT02152306</nct_id>
  </id_info>
  <brief_title>Fimasartan/Amlodipine Combination Phase III</brief_title>
  <official_title>A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University Haeundai Paik Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeju National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University Seoul Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in&#xD;
      hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with&#xD;
      hypertension who have no response to Fimasartan 60mg monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
    <description>To compare the difference of Mean Systolic Blood Pressure at 8 weeks from baseline visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline</measure>
    <time_frame>4 weeks from Baseline Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline</measure>
    <time_frame>4 and 8 weeks from Baseline Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks from Screening Visit</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Changes in Laboratory Test Results</measure>
    <time_frame>12 weeks from Screening Visit</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Changes in Electrocardiography (ECG)</measure>
    <time_frame>12 weeks from Screening Visit</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan and Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan and Amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan and Amlodipine</intervention_name>
    <arm_group_label>Fimasartan and Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Fimasartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily signed informed consent for participating in this clinical&#xD;
             trial&#xD;
&#xD;
          2. Male and Female between 20 and 75 years old&#xD;
&#xD;
          3. Patients with essential hypertension&#xD;
&#xD;
          4. Patients who is unresponsive to Fimasartan 60mg monotherapy for 4 weeks (i.e. the mean&#xD;
             SiDBP from 3 times of measurement is 140mmHg ≤ SiSBP &lt;180 mmHg)&#xD;
&#xD;
          5. Understand the trial procedures and be willing to cooperate and complete the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe Hypertension patients (SiDBP ≥ 110mmHg and/or SiSBP ≥ 180mmHg)&#xD;
&#xD;
          2. Subjects with the difference between blood pressures from a selected arm, SiDBP ≥10&#xD;
             mmHg or SiSBP ≥20 mmHg, at screening assessment&#xD;
&#xD;
          3. Secondary hypertension patients, but not limited to the following disease;(example:&#xD;
             renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of&#xD;
             the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis,&#xD;
             Cushing's syndrome, pheochromo-cytoma, polycystic kidney disease, etc.)&#xD;
&#xD;
          4. Clinically significant renal function abnormality in the laboratory results at&#xD;
             screening (i.e. serum creatine ≥ 1.5 times upper normal limit (UNL)), liver function&#xD;
             abnormality (ALT, AST ≥ 2 times upper normal limit (UNL)), severe fatty liver disease&#xD;
             that requires medication&#xD;
&#xD;
          5. Clinically significant Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded&#xD;
             5.5mmol/L)&#xD;
&#xD;
          6. Subjects with following surgical and internal disease that may affect absorption,&#xD;
             distribution, metabolism or excretion of drugs and have conditions which include the&#xD;
             following (but are not limited to): history of major gastrointestinal surgeries&#xD;
             including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass&#xD;
             graft and stapling; current active gastritis, ulcer, gastrointestinal and rectal&#xD;
             bleeding, presence of active inflammatory bowel syndrome within the past 12 months; or&#xD;
             clinically significant urinary obstruction at discretion of investigator&#xD;
&#xD;
          7. Subjects with depletion of body fluid or sodium ion not able to correct&#xD;
&#xD;
          8. Subjects with severe insulin-dependent Diabetes Mellitus (DM) or chronic DM (HbA1c&gt;9%,&#xD;
             dosage of an oral hypoglycemic agent was modified within the past 12 weeks, or use of&#xD;
             active insulin treatment at screening)&#xD;
&#xD;
          9. Subjects with severe heart disease (heart failure New York Heart Association(NYHA)&#xD;
             Class III and IV), or history of any of the followings within the past 6 months;&#xD;
             ischemic heart disease(e.g. angina pectoris, myocardial infarction), peripheral&#xD;
             vascular disease, percutaneous transluminal coronary angioplasty, or coronary artery&#xD;
             bypass graft.&#xD;
&#xD;
         10. Subjects with clinically significant ventricular tachycardia, atrial fibrillation,&#xD;
             atrial flutter or any other clinical significant arrhythmia conditions at discretion&#xD;
             of investigator.&#xD;
&#xD;
         11. Subjects with hypertrophic obstructive cardiomyopathy, severe obstructive coronary&#xD;
             artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or&#xD;
             mitral valve stenosis.&#xD;
&#xD;
         12. Subjects with severe cerebrovascular disorder (e.g. stroke, cerebral infarction or&#xD;
             cerebral hemorrhage within the past 6 months).&#xD;
&#xD;
         13. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory&#xD;
             therapy, Past or current medical history with wasting disease, autoimmune diseases&#xD;
             (e.g. rheumatoid arthritis, systemic lupus erythematosus ) or connective tissue&#xD;
             disease.&#xD;
&#xD;
         14. Subjects with known moderate or malignant retinosis (e.g. retinal hemorrhage, visual&#xD;
             disturbance or retinal microaneurysm in the past 6 months).&#xD;
&#xD;
         15. Subjects with hepatitis B (including positive test for HBsAg), hepatitis C-positive.&#xD;
&#xD;
         16. Subjects with history or evidence of abusing drugs or alcohol within the past 2 years.&#xD;
&#xD;
         17. Medical history with hypersensitivity to angiotensin II antagonist-based drugs or&#xD;
             calcium-channel blockers&#xD;
&#xD;
         18. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
         19. Pregnant women and lactating female&#xD;
&#xD;
         20. Women of childbearing potential who are not using effective contraceptive methods.&#xD;
             (Excluding subjects who had surgically sterilized. All women of childbearing potential&#xD;
             who did not have surgical sterilization must prove negative in a pregnancy test, and&#xD;
             continue to use accepted and effective contraceptive methods until the end of the&#xD;
             study in order to participate. Not accepted contraceptive method: Periodic abstinence&#xD;
             and celibacy (e.g. Basic body temperature method, menstrual cycle calculation),&#xD;
             hormonal contraceptives.&#xD;
&#xD;
         21. Subject who is participating in another trial or took other investigational product&#xD;
             within12 weeks from the screening visit&#xD;
&#xD;
         22. Medical history of all kinds of malignant tumor including leukemia and lymphoma in the&#xD;
             past 5 years&#xD;
&#xD;
         23. A subject with other reasons not specified above that, ineligible to participate in&#xD;
             this clinical trial at discretion of study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol Ho Kim, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Fimasartan and Amlodipine</keyword>
  <keyword>Antihypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

